What Yi Fang Treats: Main Uses and Benefits

Yi Fang (Valsartan) is used across therapeutic domains involving supportive symptom management for conditions characterized by heightened physiological stress and pressure. Its primary therapeutic scope includes high blood pressure, heart failure, and post-heart attack management. This medication is applied in settings marked by chronic physiological imbalance.

It is used to address symptom clusters that may become intense or disruptive, such as those related to Hypertension, Heart Failure (including Left Ventricular Dysfunction), and is relevant for easing the risk of subsequent events following a Myocardial Infarction. The medication is also relevant for easing the symptomatic manifestation of protein leakage (Albuminuria) in patients with Diabetic Nephropathy.

This approach provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. The use of Yi Fang in these contexts plays a role in managing risk factors that support long-term cardiac stability and assists with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Supportive Management of Systemic Strain

Therapeutic Focus	Primary Benefit
High Blood Pressure	Management of persistently elevated arterial pressure.
Heart Failure	Contributes to easing the overall symptom load related to organ-specific functional stress.
Organ Protection	Supports general well-being by addressing organ-specific functional stress.

Official Eligibility Profile

The eligibility for Yi Fang (Valsartan) is strictly defined by government regulatory documents, focusing on patient population and pre-existing health conditions.

Eligibility Status	Patient Population/Condition
Absolutely Contraindicated	Pregnant women (due to Fetal Toxicity Warning). Patients with known hypersensitivity to Valsartan or any component. Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
Use Prohibited	Patients with Diabetes Mellitus or moderate to severe Renal Impairment ( GFR < 60 mL/min/1.73 m^2) who are simultaneously receiving a medication containing Aliskiren (dual RAAS blockade).

---

Conditional Eligibility	Status and Requirement
Adults	Approved for all labeled uses (Hypertension, Heart Failure, Post-Myocardial Infarction).
Pediatric Patients	Approved for Hypertension only, starting at 6 years of age and older. Use is not recommended in children under 6 years or those with severe renal impairment ( GFR < 30 mL/min/1.73 m^2).
Hepatic/Renal Impairment	Use requires caution in patients with mild-to-moderate hepatic impairment or severe renal impairment. Caution is also needed for patients with renal artery stenosis.
Lactating Women	Use is not recommended while breastfeeding.

These rules establish strict non-eligibility for certain groups, such as pregnant women, and mandate careful administration and monitoring when used in patients with compromised organ function.

Interactions with other medicines and products

The interaction profile of Valsartan (Yi Fang) is governed by specific pharmacodynamic and transporter-mediated effects, as documented in official regulatory sources.

Pharmacodynamic and Contraindication Risks

Substance Category	Official Documented Restriction / Outcome
Aliskiren	Contraindicated in patients with diabetes mellitus or a GFR below 60 mL/min/1.73 m^2 (renal impairment).
Potassium-Sparing Diuretics (e.g., Spironolactone)	Co-administration may cause hyperkalemia (elevated serum potassium).
NSAIDs (including COX-2 Inhibitors)	May lead to attenuation of the blood pressure-lowering effect and increased risk of worsening renal function, particularly in elderly or renally compromised patients.
Lithium Preparations	Co-administration may result in increased serum lithium concentrations and risk of toxicity.

Transporter and Food Interactions

Substance Category	Official Documented Effect on Valsartan Exposure
OATP1B1/MRP2 Inhibitors (e.g., Ritonavir, Rifampin)	Inhibition of these transporters may increase the systemic exposure (AUC and C max) of Valsartan.
Food	Food decreases Valsartan exposure by approximately 40%; however, this is not associated with a clinically significant reduction in therapeutic effect, and the product may be taken without regard to meals.

The official documents do not mandate any specific timing or separation requirements for the administration of Valsartan relative to other medicines.

Molecular Signaling Cascade Modulation

Yi Fang acts by initiating or suppressing signaling sequences via receptor- or enzyme-mediated pathways, primarily focusing on the PI3K/AKT/Nrf2 axis. This modulation of early molecular steps influences feedback loops within the targeted pathways, thereby affecting downstream signaling required for maintaining cellular balance and the precise modulation of reactive oxygen species (ROS) levels.

---

Regulation of Cellular Survival Pathways

The formula engages mechanisms that influence cellular processes driven by distinct signaling patterns, including HIF-1alpha and the epithelial-mesenchymal transition (EMT). This occurs through the regulation of transcription factor activity that directly modulates cell proliferation and migration kinetics, consequently affecting the signaling components responsible for cell structure maintenance.

---

Anti-Inflammatory Mediator Control

The components of Yi Fang modify key pathways associated with the transcription of physiological response mediators, notably those involving TNF-alpha and PTGS-2 (COX-2). By affecting the activity of specific transcription factors that mediate inflammatory and vascular responses, the formula modulates the production rate of both inflammatory and vascular mediators.

How to use Yi Fang

The administration of Yi Fang (Valsartan) is strictly through the oral route, provided either as film-coated tablets in strengths up to 320 mg or as an oral suspension prepared for specific patient populations, such as children. It is important to note that the tablets and the oral suspension are not interchangeable on a milligram-for-milligram basis due to different systemic exposures. Administration may occur with or without food.

Dosing and Frequency

The dosing schedule is tailored to the specific condition being managed. For hypertension, the typical schedule is once daily, starting at 80 mg or 160 mg, with a maximum dose of 320 mg per day. For heart failure and post-myocardial infarction management, the regimen is standardized to twice daily (BID). Treatment is initiated at a low dose (e.g., 40 mg BID for heart failure) and gradually increased.

Titration and Special Instructions

Dose adjustments follow fixed minimum time intervals; for example, dose increases in heart failure are separated by at least two weeks to ensure safe titration to the target maintenance dose. In terms of population-specific rules, initial dosage adjustments for older adults or those with mild to moderate renal impairment are generally not required. However, for mild to moderate hepatic impairment (non-cholestasis), the maximum recommended dose is 80 mg. If a dose is missed, the instruction is to skip the forgotten dose and resume the regular schedule, rather than taking a double dose.

Research evidence / Overview of studies for Yi Fang (Valsartan)

Evidence for use in High Blood Pressure (Hypertension)

Research for Yi Fang in managing high blood pressure includes numerous large-scale, long-term Randomized Controlled Trials (RCTs) and comparative studies. These studies primarily measure changes in Systolic and Diastolic Blood Pressure (BP), aiming to understand how BP levels evolved over the study intervals. Studies consistently report measurements that described changes in both systolic and diastolic BP across various adult populations.

What remains uncertain is the relative impact of Yi Fang on preventing all major cardiovascular outcomes when compared side-by-side with every other class of blood pressure medicine, especially in certain high-risk groups.

---

Evidence for use in Chronic Heart Failure

The research base for Yi Fang in chronic heart failure relies heavily on large, pivotal RCTs, where the medicine was typically studied in patients already receiving other standard heart failure treatments. The evidence is most established for patients with reduced ejection fraction (HFrEF). Analyses of these large trials reported findings describing a pattern of difference in the combined outcome of death and hospitalization for heart failure in patients with a reduced ejection fraction. Studies observed a difference in the combined outcome that aligned with a reported difference in the number of hospitalizations in the study population.

Evidence regarding long-term effects on patients with preserved ejection fraction remains limited in monotherapy studies.

---

Evidence for use Following a Heart Attack (Post-Myocardial Infarction)

Yi Fang was evaluated in large, active-controlled RCTs following a heart attack (MI) in high-risk patients who also had evidence of heart failure or a weakened heart muscle. The primary outcome research examined was patterns of survival. Findings reported that the measurements for patterns of survival were generally comparable between Yi Fang monotherapy and a standard ACE inhibitor monotherapy. Data describing the long-term effects are limited beyond the typical follow-up duration of approximately 2.5 years for the main trial.

Common questions about Yi Fang (FAQ)

Q: What is the best time of day to take Yi Fang?

Regulatory information typically recommends taking this medication at the same time each day to help maintain steady blood levels, but specific instructions should come from your prescriber. The product information may suggest taking it with a meal or in the evening, as drowsiness is a common reported side effect.

The tablets must generally be swallowed whole, as crushing or chewing could impact the release of the medication. Consult the 'How to Use' section of the patient information.

If a dose is missed, do not take an extra dose or double the next one. Consult the patient information leaflet or your healthcare provider immediately for instructions on missed doses.

---

Q: How long does it take for Yi Fang to start working?

The time it takes to see a therapeutic response can vary among individuals. Treatment response is typically assessed over a period of time, as the medication works to address the underlying disease.

Clinical study data often indicate that an initial response may be observed after approximately 4 to 8 weeks of continuous treatment, according to the official product labeling. The goal of therapy is to manage symptoms and potentially improve quality of life, though individual results will vary.

---

Q: Can I stop taking Yi Fang if I feel better?

Any change to the treatment schedule, including stopping the medication, must be decided and managed by a qualified healthcare professional.

Stopping certain medications abruptly can be associated with risks or a return of symptoms, so it is vital to follow your doctor's specific advice on tapering or discontinuation. A healthcare provider may discuss a plan for gradually reducing the dose (tapering) if they determine it is appropriate for your specific condition and ongoing health needs.

The official requirements for the storage and disposal of Yi Fang (Valsartan) film-coated tablets are strictly governed by regulatory guidelines to ensure product integrity and safety.

---

Storage Requirements

Focus	Regulatory Mandate
Temperature and Moisture	Store at room temperature, away from excess heat and moisture (e.g., not in the bathroom).
Container Rule	Keep the medication in its original container, ensuring the container is tightly closed.
Child Safety	It is mandatory to keep the medication out of the sight and reach of children and to store it locked up.

---

Disposal Instructions

Unused or expired Yi Fang must not be disposed together with household garbage or in wastewater. Disposal must be performed in accordance with local regulations and through designated drug take-back programs to avoid release to the environment, as mandated by official environmental precautions.